MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Mitochondrial dysfunction"

  • 2022 International Congress

    A Pilot Feasibility Study of Medium Chain Triglyceride Nutritional Ketosis and Parkinson’s Disease

    A. Choi, M. Delgado, K. Chen, S. Chung, A. Courville, S. Turner, S. Yang, K. Airaghi, I. Dustin, P. Mcgurrin, M. Hallett, D. Ehrlich (Sun City, USA)

    Objective: To determine if nutritional ketosis supplemented by medium chain triglycerides (MCT) over the course of 2-3 weeks is acceptable and feasible in patients with…
  • MDS Virtual Congress 2021

    Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson’s Disease

    M. Beke, P. Mackie, C. Rusch, E. Klann, A. Gurrala, S. Chua, E. Ince, L. Almeida, A. Ramirez-Zamora (Gainesville, USA)

    Objective: To investigate the effect of exogenous ketone ester supplementation on motor and non-motor symptoms in Parkinson’s Disease (PD). Background: Animal research and human pilot…
  • MDS Virtual Congress 2021

    The mitochondrial targeted drug SBT-272 attenuates dopaminergic neuron loss, alpha-synuclein burden and neuroinflammation in a mouse model of Parkinson’s Disease

    S. Bido, J. Kūka, M. Makrecka-Kuka, G. Zheng, D. Keefe, V. Broccoli (Milan, Italy)

    Objective: To assess the preclinical efficacy of the investigational drug SBT-272 in a mouse model of Parkinson’s Disease (PD). Background: SBT-272 is a peptidomimetic drug…
  • MDS Virtual Congress 2021

    Validation of the Neuroprotective Potential of SLP-2 against alpha-synuclein neuropathology in a Mouse Model of Parkinson’s Disease

    C. Bolduc, M. Lorente Picón, S. Laouafa, J. Soliz, I. Pichler, M. Lévesque (Québec, Canada)

    Objective: We aim to validate the neuroprotective potential of SLP-2 against α-syn neuropathology and neurodegeneration of dopaminergic neurons in a mouse model of Parkinson’s disease.…
  • MDS Virtual Congress 2021

    Molecular investigation of apparently healthy heterozygous Parkin mutation carriers

    M. Castelo, A. Zanon, V. Gilmozzi, C. Klein, P. Pramstaller, A. Hicks, I. Pichler (Bolzano, Italy)

    Objective: To investigate whether apparently healthy individuals carrying a heterozygous pathogenic Parkin (PRKN) mutation show molecular phenotypes of mitochondrial dysfunction. Background: Homozygous or compound-heterozygous mutations…
  • MDS Virtual Congress 2021

    Metabolic alterations in a Drosophila model of Parkinson’s disease

    C. Solana-Manrique, F J. Sanz, I. Torregrosa, N. Paricio (Burjassot, Spain)

    Objective: Identification of metabolic alterations that could be contributing to Parkinson’s disease (PD) physiopathology and become new biomarkers or therapeutic targets for the disease. Background:…
  • MDS Virtual Congress 2021

    Reduced cerebral energy metabolism in Parkinson’s disease in contrast to Progressive Supranuclear Palsy

    J. Prasuhn, M. Göttlich, B. Ebeling, S. Kourou, F. Gerkan, C. Bodemann, S. Großer, K. Reuther, H. Hanssen, N. Brüggemann (Lübeck, Germany)

    Objective: To determine the significance of 31P-MRSI to differentiate between idiopathic Parkinson’s disease (PD), Progressive supranuclear palsy (PSP), and healthy control subjects. Background: Bioenergetic disturbances,…
  • MDS Virtual Congress 2021

    Relationship of subcortical iron deposition and mitochondrial dysfunction in patients with idiopathic Parkinson’s disease

    J. Prasuhn, M. Göttlich, F. Gerkan, S. Kourou, B. Ebeling, M. Kasten, H. Hanssen, C. Klein, N. Brüggemann (Lübeck, Germany)

    Objective: To investigate subcortical brain iron deposition as a potential predictor of the bioenergetic status in patients with idiopathic Parkinson's disease. Background: The underlying pathophysiology…
  • MDS Virtual Congress 2020

    Novel Recessive Mitochondrial Mutations Causing Leigh’s Syndrome and Movement Disorders

    B. Barton, C. Toro (Chicago, IL, USA)

    Objective: Describe discovery of novel mitochondrial mutations causing ataxia and dystonia syndromes with occurrence in childhood. Background: An African-American man at 5 years old subacutely…
  • MDS Virtual Congress 2020

    Genetic, biochemical and clinical findingss in Friedreich’s ataxia patients – relationship with the disease severity

    R. Moganty, D. Pathak, A. srivastava, s. Gulati (New Delhi, India)

    Objective: To investigate the correlation of disease severity in terms of clinical, genetic and molecular parameters in FRDA. Background: : Friedreich ataxia (FRDA) is a…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 11
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson’s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley